Prestige Consumer Healthcare Inc. Insider Trading

PBH

Last 12 months

Insiders sold 424K and bought nothing on the open market.

27% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Feb 2018.

Net open-market

−424K

0 buys · 7 sales

Under a 10b5-1 plan

27%

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

Feb 2018

Feb 12, 2018

Get an email when PBH's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 11	Jeffrey Zerillo Senior VP Operations	Sold10b5-1 plan	351	$52.28	18K	0.8%	Form 4
May 7	Jeffrey Zerillo Senior VP Operations	Sold10b5-1 plan	305	$54.36	17K	0.7%	Form 4
May 5	Jeffrey Zerillo Senior VP Operations	SoldNo plan	1,207	$54.99	66K	2.7%	Form 4
May 5	Jeffrey Zerillo Senior VP Operations	Sold10b5-1 plan	346	$55.32	19K	0.8%	Form 4
Feb 11	Jeffrey Zerillo Senior VP Operations	SoldNo plan	1,000	$65.93	66K	2.4%	Form 4
Nov 28, 2025 – Dec 1, 2025	Jeffrey Zerillo Senior VP Operations	Sold10b5-1 plan 2 parts	1,000	$60.00 average	60K	2.3%	Form 4
Nov 25, 2025	John E Byom Director	SoldNo plan	3,000	$59.35	178K	5.5%	Form 4
Mar 10, 2025	Mary Beth Fritz SVP Quality & Regulatory	Sold10b5-1 plan	1,678	$90.00	151K	8.9%	Form 4
Mar 3, 2025	Mary Beth Fritz SVP Quality & Regulatory	Sold10b5-1 plan	6,297	$85.39	538K	25%	Form 4
Feb 11, 2025	Adel Mekhail EVP, Marketing & Sales	SoldNo plan 2 parts	11,083	$86.55 average	959K	38%	Form 4
Nov 19, 2024	Ronald M. Lombardi Chief Executive Officer	SoldNo plan 2 parts	10,875	$82.60 average	898K	3.3%	Form 4
Nov 18, 2024	Ronald M. Lombardi Chief Executive Officer	SoldNo plan 2 parts	82,237	$82.56 average	$6.79M	20%	Form 4
Nov 12, 2024	William P'Pool See Remarks	SoldNo plan	8,987	$81.85	736K	31%	Form 4
Nov 12, 2024	Christine Sacco Chief Financial Officer	SoldNo plan	24,686	$82.01	$2.02M	45%	Form 4
Nov 12, 2024	Adel Mekhail EVP, Marketing & Sales	SoldNo plan	9,063	$82.00	743K	33%	Form 4
Nov 12, 2024	Mary Beth Fritz SVP Quality & Regulatory	SoldNo plan 2 parts	9,885	$81.97 average	810K	34%	Form 4

May 1110b5-1 plan
Jeffrey Zerillo
Senior VP Operations · sold 351 at $52.28
18K
0.8% of stake
May 710b5-1 plan
Jeffrey Zerillo
Senior VP Operations · sold 305 at $54.36
17K
0.7% of stake
May 5No plan
Jeffrey Zerillo
Senior VP Operations · sold 1,207 at $54.99
66K
2.7% of stake
May 510b5-1 plan
Jeffrey Zerillo
Senior VP Operations · sold 346 at $55.32
19K
0.8% of stake
Feb 11No plan
Jeffrey Zerillo
Senior VP Operations · sold 1,000 at $65.93
66K
2.4% of stake
Nov 28, 2025 – Dec 1, 202510b5-1 plan
Jeffrey Zerillo
Senior VP Operations · sold 1,000 at avg $60.00
60K
2.3% of stake
Nov 25, 2025No plan
John E Byom
Director · sold 3,000 at $59.35
178K
5.5% of stake
Mar 10, 202510b5-1 plan
Mary Beth Fritz
SVP Quality & Regulatory · sold 1,678 at $90.00
151K
8.9% of stake
Mar 3, 202510b5-1 plan
Mary Beth Fritz
SVP Quality & Regulatory · sold 6,297 at $85.39
538K
25% of stake
Feb 11, 2025No plan
Adel Mekhail
EVP, Marketing & Sales · sold 11,083 at avg $86.55
959K
38% of stake
Nov 19, 2024No plan
Ronald M. Lombardi
Chief Executive Officer · sold 10,875 at avg $82.60
898K
3.3% of stake
Nov 18, 2024No plan
Ronald M. Lombardi
Chief Executive Officer · sold 82,237 at avg $82.56
$6.79M
20% of stake
Nov 12, 2024No plan
William P'Pool
See Remarks · sold 8,987 at $81.85
736K
31% of stake
Nov 12, 2024No plan
Christine Sacco
Chief Financial Officer · sold 24,686 at $82.01
$2.02M
45% of stake
Nov 12, 2024No plan
Adel Mekhail
EVP, Marketing & Sales · sold 9,063 at $82.00
743K
33% of stake
Nov 12, 2024No plan
Mary Beth Fritz
SVP Quality & Regulatory · sold 9,885 at avg $81.97
810K
34% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PBH, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PBH

CompareIntrinsic value

APLSApellis Pharmaceuticals, Inc.

$3.10+3.29%83

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

Held by ETFs

PBH is in 96 US ETFs. The largest of them, with PBH's weight in each:

Spot a number that looks wrong? Check it in PBH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PBH

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.